In gynecological oncology, this combined anti-PD-1 and anti-LAG-3 (REGN3767) antibody approach is under clinical investigation for the treatment of early-stage high-risk HER2− breast cancer patients (NCT01042379). Here, LAG3 is linked to breast cancer.